


26<sup>TH</sup> EORTC-NCI-AACR SYMPOSIUM ON  
**'MOLECULAR TARGETS  
& CANCER THERAPEUTICS'**

**STATISTICS  
REPORT**





Organised by





**18-21 NOVEMBER  
2014  
BARCELONA,  
SPAIN**

## Participants



Total Number of Participants **1994**




## Top 10 Countries by Participation



## Delegates Participation by Continent Overview



## Profession of delegates



## Scientific Programme Related Statistics

Total Abstracts Submitted **936**

Posters **576**

Oral **19**


Rejected **278**

Total at General Submission **873**


Late-Breaking Abstracts Total **63**

Oral Presentations **11**

Rejected **52**








## Top 20 Abstract Submission by Country



## App and Website

### App Downloads



	Total number of page views:	<b>249 069</b>
	Unique page views:	<b>159 432</b>
 #ENA2014	Tweets using #ENA2014	<b>1 212</b>
	Twitter Impressions:	<b>2 133 192</b>

## Top 5 Visited Sessions

Proffered Paper Session
Novel Mechanisms for Drug Resistance
Proffered Paper Session
Epigenetic Targets
Is the Genomic Landscape Changing the Outcome for Cancer Patients?



**EORTC  
NCI  
AACR  
2016**

## 'MOLECULAR TARGETS AND CANCER THERAPEUTICS'

18 – 21 OCTOBER 2016

MUNICH, GERMANY

### 28<sup>TH</sup> EORTC-NCI-AACR SYMPOSIUM ON 'MOLECULAR TARGETS AND CANCER THERAPEUTICS'



The 28<sup>th</sup> EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics' is the premier international meeting on drug development, innovative approaches, targeted agents including biomarkers and translational research. This annual meeting takes place alternately in the USA and in Europe (since 1978).

The symposium brings together academics, scientists and representatives from the pharmaceutical industry to discuss and exchange ideas to foster innovations in drug and cancer therapeutic development, with a particular focus on early clinical application.

During the last few years, numerous innovative agents have been discovered as a result of tremendous developments in the understanding of the molecular basis of cancer.

Further clinical progress in cancer treatment will be accomplished mainly through the conduct of translational research projects, efficient new drug development and the execution of innovative early clinical trial designs. This requires a joint and global approach and early and optimal exchange of information. Therefore, the Symposium will ensure the maximum amount of interaction and discussion through an exciting range of plenary sessions and lively workshops.

For forthcoming announcements about the **28<sup>th</sup> EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics'** please bookmark [www.eortc.be](http://www.eortc.be), or contact the Secretariat directly:

c/o ECCO – the European CanCer Organisation  
Avenue E. Mounier, 83  
B-1200 Brussels  
Belgium

Tel.: +32 (0) 2 775 02 01  
Fax: +32 (0) 2 775 02 00

E-mail: [ena2016@ecco-org.eu](mailto:ena2016@ecco-org.eu)  
[www.ecco-org.eu/ENA](http://www.ecco-org.eu/ENA)